home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471084.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
3KB
|
52 lines
Document 1084
DOCN M9471084
TI Epstein-barr virus-associated lymphoproliferative disease (EBV-LPD) in
the severe combined immune deficient human/mouse model: prevention with
low dose interleukin-2 suppresses production of human interleukin-6 and
interleukin-10 (Meeting abstract).
DT 9409
AU Baiocchi R; Sullivan L; Tan J; Narula S; Caligiuri M; Dept of Medicine,
Roswell Park Cancer Inst., Buffalo, NY 14263
SO Proc Annu Meet Am Soc Clin Oncol; 13:A969 1994. Unique Identifier :
AIDSLINE ICDB/94600965
AB When severe combined immune deficient (SCID) mice are reconstituted with
human PBL (hu-PBL-SCID) from individuals seropositive for Epstein-Barr
virus (EBV), a fatal EBV-associated lymphoproliferative disease
(EBV-LPD) of human B cell origin develops in the majority of the
hu-PBL-SCID mice. These EBV-LPD tumors have a surface phenotype and
karyotype which bear striking resemblance to EBV-LPD seen in organ
transplant recipients and HIV infection. Thus, the hu-PBL-SCID mouse
model shows promise for understanding both the pathogenesis and
treatment of EBV-induced lymphomagenesis in immunocompromised
individuals. In a randomized placebo-controlled study, we recently
demonstrated that daily subcutaneous administration of low dose IL-2 can
prevent the development of EBV-LPD in the hu-PBL-SCID mouse (Baiocchi
and Caligiuri, Blood, 82 Suppl 1;385a). 80% of mice treated with placebo
died of EBV-LPD while 22% of rIL-2-treated mice died of EBV-LPD
(p=0.0008). In the present report, we characterize the production of two
human cytokines, interleukin-10 (huIL-10) and interleukin-6 (huIL-6), in
placebo- and IL-2-treated hu-PBL-SCID mice. Tumor bearing animals had
strikingly elevated serum concentrations of huIL-10 and huIL-6 while
those without tumor had low or undetectable levels (p less than or equal
to 0.005 for both cytokines). Northern analysis of RNA isolated from 11
EBV-LPD tumors revealed that 91% (10/11) of tumors expressed huIL-10
ligand mRNA and 82% expressed mRNA for huIL-10 receptor (huIL-10R). The
presence of a functional huIL-10R on fresh tumor specimens was confirmed
through radiolabeled IL-10 binding studies. These results suggest that
production of huIL-10 and huIL-6 may be important in the pathogenesis of
EBV-LPD in the hu-PBL-SCID model, and that IL-2 may prevent EBV-LPD
through counter-regulation of B cell stimulatory cytokine production.
Studies utilizing neutralizing antibodies to huIL-10 and huIL-6 in the
absence of IL-2 therapy are underway.
DE Animal Blotting, Northern Comparative Study Herpesviridae
Infections/*IMMUNOLOGY/MICROBIOLOGY/*PREVENTION & CONTROL *Herpesvirus
4, Human/ISOLATION & PURIF Human Interleukin-10/*BIOSYNTHESIS
Interleukin-2/*THERAPEUTIC USE Interleukin-6/*BIOSYNTHESIS
Lymphoproliferative Disorders/*IMMUNOLOGY/MICROBIOLOGY/ *PREVENTION &
CONTROL Mice Mice, SCID RNA, Messenger/ANALYSIS RNA, Viral/ANALYSIS
MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL CLINICAL TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).